(Adnkronos Health) – The joint comment from the associations that also represent adult patients with neurofibromatosis in Italy – Ananas Aps; National Association for Aid for Neurofibromatosis Friendship and Solidarity: Anf–Neurofibromatosis Association and Linfa-Let’s Fight Together Against Neurofibromatosis Aps – is also positive. “The availability of selumetinib also for adults with plexiform neurofibromas represents a significant achievement for the entire Nf1 community,” they state. “This result offers new perspectives to people living with the disease and their families, and is the recognition of a care need that has long gone unanswered. It is also a demonstration of what can be achieved when associations, clinicians, institutions, and industry work together with a common goal: to improve the lives of people with Nf1 and continue to advance treatment opportunities.”
“The extension of selumetinib’s indication for the treatment of plexiform neurofibromas in adults with Nf1 marks a significant advancement for these patients who, until now, had limited therapeutic options, also contributing to ensuring continuity of care during the delicate transition from adolescence to adulthood,” comments Anna Chiara Rossi, VP and General Manager of Alexion, AstraZeneca Rare Disease. “This result confirms Alexion’s constant commitment to rare diseases and the search for solutions capable of addressing unmet needs, with the aim of concretely improving the management of people living with these pathologies.” Selumetinib – the note concludes – has been approved in the United States, Europe, Japan, and other countries for the treatment of adult patients with Nf1 suffering from symptomatic and inoperable PNs, and further regulatory reviews are underway.